2021
DOI: 10.1007/s41999-021-00504-5
|View full text |Cite
|
Sign up to set email alerts
|

Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications

Abstract: Purpose In the pathogenesis of severe COVID-19 complications, derangements of renin–angiotensin–aldosterone system (RAAS), vascular endothelial dysfunction leading to inflammation and coagulopathy, and arrhythmias play an important role. Therefore, it is worth considering the use of currently available drugs to protect COVID-19 patients with cardiovascular diseases. Methods We review the current experience of conventional cardiovascular drugs [angiotensin-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 148 publications
(226 reference statements)
1
2
0
Order By: Relevance
“…Overall, our observation that the outpatient use of statins, ACEI/ARBs and anticoagulants were protective against adverse outcomes in patients diagnosed with COVID-19 is consistent with a review conducted by Alves et al 52 and previous studies that assessed premorbid use of these classes of cardiovascular medications. 53 , 54 , 55 , 56 , 57 It is important to note, that ours is, to our knowledge, the largest matched, national comparative analysis of cardiovascular medications and COVID-19 outcomes thus far.…”
Section: Discussionsupporting
confidence: 91%
“…Overall, our observation that the outpatient use of statins, ACEI/ARBs and anticoagulants were protective against adverse outcomes in patients diagnosed with COVID-19 is consistent with a review conducted by Alves et al 52 and previous studies that assessed premorbid use of these classes of cardiovascular medications. 53 , 54 , 55 , 56 , 57 It is important to note, that ours is, to our knowledge, the largest matched, national comparative analysis of cardiovascular medications and COVID-19 outcomes thus far.…”
Section: Discussionsupporting
confidence: 91%
“…Despite this large number of studies on this topic, only a few studies have been performed so far to investigate what happens at an older age (9), such as that of our study population (mean age: 87.4 ± 6.1 years). A French observational study, conducted in a geriatric department, showed a lower mortality rate in older patients (mean age: 86.3 ± 8.0 years) taking ACEi/ARB compared with patients not taking these drug classes (29).…”
Section: Discussionmentioning
confidence: 99%
“…After initial unfounded speculations questioning the safety of RASi in COVID-19, extensive literature has been published on this topic, disproving those initial fears and confirming either neutral or even protective effects of RASi on severity and mortality for COVID-19 (8). However, the clinical evidence in the older population, which is both the one most treated with RASi and the one most at risk for COVID-19 morbidity and mortality, is still scarce (8,9). Therefore, the aim of our study was to evaluate the association between RASi therapy and inhospital mortality in patients aged 80 years and older admitted for COVID-19.…”
Section: Introductionmentioning
confidence: 99%